Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is scheduled to release its earnings data after the market closes on Wednesday, November 1st.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.28) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.05). Ironwood Pharmaceuticals had a negative return on equity of 333.83% and a negative net margin of 52.97%. The company had revenue of $65.10 million during the quarter, compared to analysts’ expectations of $70.00 million. During the same quarter last year, the business earned ($0.16) earnings per share. The business’s quarterly revenue was up 19.7% on a year-over-year basis. On average, analysts expect Ironwood Pharmaceuticals to post $-1.13 EPS for the current fiscal year and $-0.53 EPS for the next fiscal year.

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ IRWD) opened at 14.58 on Wednesday. The firm has a 50-day moving average of $15.77 and a 200 day moving average of $16.77. Ironwood Pharmaceuticals, Inc. has a one year low of $12.48 and a one year high of $19.94. The stock’s market capitalization is $2.18 billion.

A number of equities analysts have commented on IRWD shares. BidaskClub upgraded shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Zacks Investment Research upgraded shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 17th. Wells Fargo & Company set a $19.00 target price on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, July 22nd. Wood & Company downgraded shares of Ironwood Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Friday, July 21st. Finally, ValuEngine upgraded shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $18.29.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Earnings History for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.